The Next Biotech Index comprises the 25 biotech companies listed on NYSE Euronext’s European markets: Euronext and Alternext, representing € 4.7 billion in market capitalization (as per May 26, 2008), making Euronext the Eurozone leading exchange in terms of the number of biotech companies listed and market capitalization.
The “Next Biotech Index” enables investors, fund managers and issuers to track the performance of the fast-growing and innovative Biotech sector at a European level.
Martine Charbonnier, NYSE Euronext’s Head of European listings, said: “The new Next Biotech Index confirms NYSE Euronext’s leading position in the biotech sector and demonstrates its commitment to provide tailored and innovative tools that help biotech companies listed on its market to get the visibility and growth opportunities they need. It is a true benchmark for the performance of the European biotech sector and is an excellent choice for investors who wish to track the performance of this fast-growing sector.”
Since launch on 7 April 2008 the Next Biotech Index has outperformed the market, showing an increase of 8.1% (as per May 26, 2008). -- www.euronext.com
